Sanofi (NASDAQ:SNY) Lowered to “Buy” Rating by Wall Street Zen

Wall Street Zen lowered shares of Sanofi (NASDAQ:SNY) from a strong-buy rating to a buy rating in a research note issued to investors on Saturday.

Several other equities research analysts also recently issued reports on SNY. Citigroup assumed coverage on shares of Sanofi in a research note on Tuesday, January 27th. They set a “neutral” rating for the company. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research report on Monday, December 8th. TD Cowen reiterated a “hold” rating on shares of Sanofi in a report on Tuesday, December 30th. UBS Group restated a “neutral” rating on shares of Sanofi in a research note on Friday, January 16th. Finally, Bank of America lowered Sanofi from a “buy” rating to a “neutral” rating in a research note on Thursday, February 12th. Five analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, Sanofi currently has an average rating of “Hold” and an average target price of $62.67.

Sanofi Stock Performance

Sanofi stock opened at $46.76 on Friday. The company has a market cap of $114.05 billion, a price-to-earnings ratio of 12.99, a price-to-earnings-growth ratio of 1.21 and a beta of 0.45. Sanofi has a 12 month low of $44.62 and a 12 month high of $60.12. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.09 and a quick ratio of 0.29. The stock’s 50-day moving average is $47.55 and its 200-day moving average is $48.56.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Caprock Group LLC bought a new stake in shares of Sanofi in the 3rd quarter worth about $1,347,000. Assetmark Inc. lifted its position in shares of Sanofi by 25.0% during the third quarter. Assetmark Inc. now owns 357,172 shares of the company’s stock worth $16,859,000 after purchasing an additional 71,356 shares during the last quarter. Thrivent Financial for Lutherans grew its stake in Sanofi by 10,152.1% in the third quarter. Thrivent Financial for Lutherans now owns 2,200,107 shares of the company’s stock worth $103,846,000 after purchasing an additional 2,178,647 shares in the last quarter. Willis Investment Counsel increased its holdings in Sanofi by 11.3% in the third quarter. Willis Investment Counsel now owns 556,700 shares of the company’s stock valued at $26,276,000 after buying an additional 56,500 shares during the last quarter. Finally, Hantz Financial Services Inc. raised its stake in Sanofi by 43.1% during the third quarter. Hantz Financial Services Inc. now owns 80,832 shares of the company’s stock valued at $3,815,000 after buying an additional 24,328 shares in the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.